Linda Mileshkin

B7-H4‒directed antibody-drug conjugate AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors: the Phase 1/2a (BLUESTAR), first-in-human study

B7-H4 is a promising antibody-drug conjugate (ADC) target with high expression in several solid tumors and limited expression in normal tissue. B7-H4 negatively regulates T-cell function, and high expression of B7-H4 is associated with disease progression. AZD8205 (puxitatug samr...